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Abstract Triple-negative breast cancer is associated with
early recurrence and low survival rates. Several trials
investigate the safety of a more conservative approach of
axillary treatment in clinically T1-2N0 breast cancer. Tri-
ple-negative breast cancer comprises only 15 % of newly
diagnosed breast cancers, which might result in insufficient
power for representative results for this subgroup. We
aimed to provide a nationwide overview on the occurrence
of (regional) recurrences in triple-negative breast cancer
patients with a clinically T1-2N0 status. For this cohort
study, 2548 women diagnosed between 2005 and 2008 with
clinically T1-2N0 triple-negative breast cancer were
selected from the Netherlands Cancer Registry. Follow-up
data until 2014 were analyzed using Kaplan–Meier. Sen-
tinel lymph node biopsy was performed in 2486 patients,
and (completion) axillary lymph node dissection in 562
patients. Final pathologic nodal status was pN0 in 78.5 %,
pN1mi in 4.5 %, pN1 in 12.3 %, pN2–3 in 3.6 %, and pNx
in 1.1 %. During a follow-up of 5 years, regional recurrence
occurred in 2.9 %, local recurrence in 4.2 % and distant
recurrence in 12.2 %. Five-year disease-free survival was
78.7 %, distant disease-free survival 80.5 %, and 5-year
overall survival 82.3 %. Triple-negative clinically T1-2N0
breast cancer patients rarely develop a regional recurrence.
Their disease-free survival is more threatened by distant
recurrence, affecting their overall survival. Consequently, it
seems justified to include triple-negative breast cancer
patients in randomized controlled trials investigating the
safety of minimizing axillary staging and treatment.
Keywords Breast neoplasms  Triple-negative breast
cancer  Follow-up  Recurrence  Sentinel lymph node
biopsy  Axillary lymph node dissection
Introduction
Breast cancer knows a large heterogeneity of tumors char-
acterized by several molecular profileswith different clinical
behaviors and responses to therapy. In clinical practice,
breast cancer patients are generally classified by clinical and
histological tumor characteristics, axillary lymph node sta-
tus, hormonal receptor status, and human epidermal growth
factor receptor 2 (HER2) status [1–3]. Based on receptor
status, several breast cancer subtypes are classified. One of
these subtypes is triple-negative breast cancer (TNBC),
which is characterized by the absence of (over)expression of
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estrogen receptor (ER), progesterone receptor (PR), and
HER2 receptor. TNBC is found in approximately 15 % of
newly diagnosed breast cancer patients [2, 4, 5] and is more
prevalent in younger patients (\50 years) [2, 3, 4, 6, 7].
TNBC is associated with amore aggressive nature compared
to other breast cancer subtypes, reflected by a larger tumor
size, higher tumor grade, early peak of recurrence, and a
worse 5-year overall survival rate [2, 5, 8, 9]. To date, the
only systemic treatment option for TNBC patients is
chemotherapy. Multiple-targeted drugs are at various stages
of development for TNBC. However, no effective-targeted
therapy has been detected so far [5, 10].
Currently, there is a trend toward a more conservative
approach of axillary staging and treatment in breast cancer.
The aim is to decrease the axillary morbidity rate, while
maintaining excellent regional control without affecting
overall survival. Randomized controlled trials revealed that
completion axillary lymph node dissection (ALND) can be
safely omitted in clinically T1-2N0 breast cancer in case of
limited metastatic sentinel lymph nodes (SLNs) and breast
conserving treatment [11, 12]. An ongoing trial investi-
gates whether this is also applicable for SLN-positive
patients undergoing a mastectomy (BOOG 2013-07). Fur-
ther, the value of the SLN biopsy (SLNB) in current era is
being questioned. Several trials randomize clinically
T1(-2)N0 patients treated with breast conserving therapy to
SLNB or ‘watchful waiting’ (BOOG 2013-08; SOUND;
NCT01821768) [13].
Due to the low incidence of TNBC, only a minority of
patients in these study populations represents TNBC
patients, leading to insufficient power for representative
results regarding this subgroup. Furthermore, clinicians are
cautious on performing less axillary staging and treatment
in TNBC, mainly because of its association with the
aggressive nature and fewer systemic treatment options in
this subtype of breast cancer patients.
It is questionable whether TNBC patients are at risk for
higher regional recurrence rates and poorer overall survival
when limiting or omitting axillary treatment. In the literature,
studies on recurrence patterns in TNBC mainly focus on local
anddistant recurrence andoverall survival. In order to gainmore
insight into recurrences in TNBC patients, and for regional
recurrence in particular, we aimed to provide a nationwide
overviewon the occurrence of recurrence andoverall survival in
TNBC patients with a clinically T1-2N0 status.
Methods
Study population and data collection
All consecutive women of 18 years and older with primary
invasive, clinically T1-2N0 unilateral TNBC diagnosed
between 2005 and 2008, were identified from the Nether-
lands Cancer Registry, hosted by the Comprehensive
Cancer Organisation the Netherlands (IKNL). Data are
gathered by specially trained data managers in all hospitals
in the Netherlands based on notification from the auto-
mated pathology archive (PALGA). Patients undergoing
primary systemic treatment were not included in the
selection. Patients diagnosed prior to 2005 or after 2008
were not included due to lack of registration of HER2
status, or lack of follow-up data, respectively. The fol-
lowing data were provided anonymized: age, performed
surgical procedure(s), administration of adjuvant
chemotherapy, adjuvant radiotherapy, histology of primary
tumor and lymph nodes (i.e., tumor type, size, grade, and
receptor status), time to event (local, regional, and distant
event), vital status, and date of death or last day of follow-
up. Five-year follow-up data on first events were available
for every patient. Only first events were available, but
included all events that occurred within a time frame of
3 months after diagnosis of the first event. Vital status was
available up to December 31, 2014. Data were collected
directly from patient records by employees of the Nether-
lands Cancer Registry.
Axillary lymph node staging
A clinically node negative status was defined in the 2005
Dutch breast cancer guideline as negative physical exam-
ination and axillary ultrasound [14]. Tissue sampling was
recommended in case of a suspicious lymph node on
axillary ultrasound. An SLNB was advised for clinically
node-negative patients, followed by a completion ALND in
case of a metastasis in the SLN. Isolated tumor cells were
considered as pathologically node negative.
Pathological technique
The 2005 Dutch breast cancer guideline recommended to
completely include SLNs of up to 0.5 cm, to half SLNs of
0.5–1.0 cm, and fully imbed SLNs greated than 1 cm in
lammellas of 0.2 cm. It was furthermore recommended to
section each paraffin block at three levels with 250-microm-
eter intervals, but this may have varied between pathology
laboratories. If no metastasis was detected with hematoxylin
and eosin, immunohistochemical staining was adviced.
Lymph nodes of the (completion) ALND specimen were
embedded in paraffin after formalin fixation and sliced with
a recommended maximum thickness of 3 mm, followed by
hematoxylin and eosin staining.
Each lymph node was registered according to patho-
logical findings: negative (pN0), or as isolated tumor cell
(pN0(i?); B0.2 mm), micrometastasis (pN1mi; 0.2 mm
B2.0 mm), or macrometastasis (pN1-3;[2.0 mm).
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Tumors were graded according to the modified Bloom–
Richardson grading system [15]. The ER and PR status was
determined by immunohistochemistry and scored using
\10 % of tumor staining as the negative cut off. The
HER2 receptor status was determined by immunohisto-
chemistry and recorded as negative in case of 0 or ?1
staining, and positive in case of ?3 staining. Fluorescence
in situ hybridization analyses was performed in case of ?2
staining.
Adjuvant chemotherapy recommendations
The 2005 Dutch breast cancer guideline recommended
adjuvant chemotherapy for patients aged\70 years with a
pathological N? status [14]. Furthermore, adjuvant
chemotherapy was recommended in patients aged
\70 years with a pathological N0 status in case of a tumor
size C3.0 cm, a tumor size of 2–3 cm and grade 2–3, or a
tumor size of 1–2 cm and grade 3. For patients aged
B35 years, adjuvant chemotherapy was also considered in
case of a tumor size[1 cm or B1 cm and grade 2–3. As
regards to patients aged C70 years, no standard advice was
provided due to lack of evidence for benefit of
chemotherapy in this patient group [14].
The adjuvant chemotherapy regimen mostly consisted of
5 cycles of fluorouracil-epirubicin-cyclophosphamide
(FEC), or 6 cycles of docetaxel/paclitaxel-adriamycin-cy-
clophosphamide (TAC) [14].
Adjuvant radiation therapy indications
Breast conserving therapy consisted of breast conserving
surgery followed by whole breast radiotherapy, with a
fractionation scheme equivalent to 25 9 2 Gy, 5 fraction
per week [14]. A boost could be considered in patients
aged \60 years or in case of focal irradicality. Chest
wall irradiation following mastectomy was indicated in
case of irradicality, invasion of pectoralis muscle or
skin, or a pathological T3-4 status. Periclavicular radi-
ation therapy (including breast or chest wall) was indi-
cated in case of a pathological N2-3 status or a tumor-
positive axillary top, with administration of 50 Gy
fractionated irradiation [14].
Statistical analysis
Primary endpoint of our study is regional recurrence rate
within 5 years. A regional recurrence was registered by the
Netherlands Cancer Registry as an event in lymph nodes of
ipsilateral axilla, infraclavicular region, intramammary, or
in the internal mammary lymph node chain. Secondary
endpoints are local recurrence rate, distant recurrence rate,
disease-free survival, distant disease-free survival, and
overall survival. A local recurrence was registered as an
event in the ipsilateral breast (or overlying skin) with
similar morphologic characteristics as the primary tumor.
Events located elsewhere in the body were registered as
distant recurrence. Employees of the Netherlands Cancer
Registry consulted the treating physician in case there was
doubt about the occurrence of a recurrence.
Disease-free survival was defined as the time interval
from date of diagnosis to a local, regional or distant
recurrence, or death from any cause, whichever occurred
first. Distant disease-free survival was defined as the time
interval from date of diagnosis to a distant recurrence, or
death from any cause, whichever occurred first. Overall
survival was defined as the time interval between date of
diagnosis and December 31, 2014 or date of death from any
cause. Patients who were alive and disease-free were
censored at the last day of follow-up (December 31, 2014).
Descriptive categorical data are presented as proportions
and absolute numbers. Continuous variables are presented
as means with standard deviations. Kaplan–Meier method
was used to estimate the event rates at 5 years of follow-
up. Statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS), version 20.0 (IBM
Corporation, Armonk, NY, USA). A p value of\0.05 was
considered statistically significant.
Results
Patient demographics and tumor characteristics
A total of 2548 women with clinically T1-2N0 TNBC were
identified from the Netherlands Cancer Registry. In this
cohort, the mean age at diagnosis was 56 years (range
20–95), with 36 % of patients aged B50 years. Patients
demographics and tumor characteristics are presented in
Table 1. The majority of patients had a clinically T1 status
(63.5 %) and a grade 3 tumor (73.6 %). Breast conserving
therapy was performed in 63.7 %, a mastectomy in 29.9 %,
mastectomy with adjuvant radiation therapy in 4.6 %, and
lumpectomy-only in 1.8 %.
The SLNB was performed in 2486 patients (97.6 %) and
54 patients (2.1 %), primarily underwent an ALND (Fig. 1).
The SLN was negative in 1875 patients (75.4 %), not found
in 11 (0.4 %), showed isolated tumor cells in 73 (2.9 %),
micrometastasis in 117 (4.7 %), and macrometastasis in 392
patients (15.8 %). A completion ALND was performed in
508 patients. Final pathological lymph node status of all
2548 patients was pN0 in 78.5 %, pN1mi in 4.5 %, pN1 in
12.3 %, pN2 in 2.5 %, pN3 in 1.1 %, and pNx in 1.1 %.
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Adjuvant chemotherapy was administered to 1534
patients (60 %). Administration of adjuvant chemotherapy
per age category is presented in Table 2. In patients aged
B70 years, 73 % received adjuvant chemotherapy.
Outcome
During a follow-up of 5 years, 328 patients experienced a
solitary recurrence: 25 patients (1.0 %) a regional recur-
rence, 60 patients (2.4 %) a local recurrence, and 243
patients (9.5 %) a distant recurrence. Concomitant disease
occurred in another 75 patients: a local and regional
recurrence in 10 patients (0.4 %), a local and distant
recurrence in 25 patients (1.0 %), a regional and distant
recurrence in 28 patients (1.1 %), and a local, regional, and
distant recurrence in 12 patients (0.5 %).
Median time to the detection of any recurrence was
1.7 years (range 0.1–5.0 years), and in 75 % of the patients
the recurrence was detected within 3 years after breast
cancer diagnosis (interquartile range (IQR) 1.0–2.8 years).
Five-year disease-free survival, and distant disease-free
survival was 78.7 and 80.5 %, respectively. Median fol-
low-up for overall survival was 7.7 years (IQR 6.2-8.8),
with a 5-year overall survival of 82.3 %, and 10-year
overall survival of 72.2 %.
Regional recurrences
A total of 75 patients (2.9 %) experienced a regional
recurrence in our cohort, of whom 25 (1.0 %) a solitary
regional recurrence, and 50 (1.9 %) concomitant local and/
or distant disease. Patient demographics and tumor char-
acteristics at initial diagnosis of the 75 patients are pre-
sented in Table 3. An SLNB was performed for axillary
staging after diagnosis in 74 patients, revealing no metas-
tases in 37 patients (50 %), isolated tumor cells in two
patients (3 %), micrometastasis in 5 patients (7 %), and
macrometastasis in 24 patients (32 %). In two patients, the
SLN was not found; in four patients, results were unknown;
and in one patient, no SLNB was performed. A (comple-
tion) ALND was performed in 30 patients. Final patho-
logical lymph node status was pN0 in 39 patients (52.0 %),
pN0i? in two patients (2.7 %), pN1mi in 5 patients
(6.7 %), pN1 in 19 patients (25.3 %), pN2 in three patients
(4.0 %), pN3 in two patients (2.7 %), and unknown in five
patients. Adjuvant chemotherapy was administered to 45
patients.
The median time to the detection of the regional
recurrence was 1.6 years (range 0.1–4.9). In 25 % of the
patients, the regional recurrence was already detected
within the first year after breast cancer diagnosis, and in
75 % within 2.5 years (IQR 0.8–2.5 years).
Therewere 16 deaths among the 25 patientswith a solitary
regional recurrence and 45 deaths in case of concomitant
local and/or distant recurrence, resulting in a 5-year overall
survival of 28.4 %. The median time to death was 3.6 years
(range 0.3–9.8). No additional statistical analyses were
performed given the small number of events.
Table 1 Patient demographics and tumor characteristics
Characteristic Value
Number of Patients 2548
Age
Mean (SD) 56 (14)
Range 20–95
Clinical T-stadium, n (%)
cT1 1618 (63.5)
cT2 930 (36.5)
Local treatment breast, n (%)
Breast conserving therapy 1624 (63.7)
Mastectomy 761 (29.9)
Mastectomy and radiotherapy 118 (4.6)
Lumpectomy-only 45 (1.8)
Axillary surgery, n (%)
SLNB only 1978 (77.6)
ALND 54 (2.1)
SLNB and completion ALND 508 (19.9)
No axillary surgery 8 (0.3)
Pathological T-stadium, n (%)
pT1 1405 (55.1)
pT2 1095 (43.0)
pT3 34 (1.3)
pT4 3 (0.1)
Unknown 11 (0.4)
Pathological N-stadium, n (%)
pN0 1929 (75.7)
pN0(i?) 72 (2.8)
pN1mi 115 (4.5)
pN1 313 (12.3)
pN2 64 (2.5)
pN3 27 (1.1)
Unknown 28 (1.1)
Tumor type, n (%)
Ductal 1275 (83.4)
Lobular 47 (3.1)
Other 207 (13.5)
Grade (Bloom–Richardson), n (%)
Grade 1 106 (4.2)
Grade 2 470 (18.4)
Grade 3 1876 (73.6)
Unknown 96 (3.8)
N number of cases, SD standard deviation, SLNB sentinel lymph node
biopsy, ALND axillary lymph node dissection
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Discussion
The aim of this study was to provide a nationwide over-
view on the occurrence of regional recurrences in patients
with TNBC and a clinically T1-2N0 status, in the context
of the randomized controlled trials investigating the safety
of minimizing axillary staging and treatment. In this Dutch
nationwide registry TNBC population, 2.9 % of the
patients developed a regional recurrence during 5 years of
follow-up. Most were detected within 3 years after diag-
nosis. Distant recurrences occurred more frequently, in
12 %. Regional recurrences represent only a minor part of
the events that occur in TNBC.
In the present cohort of 2548 TNBC patients, all patients
were staged as clinically T1-2N0. Preoperative staging
included a negative axillary ultrasound, which is known to
decrease the rate of extensive lymph node disease in par-
ticular [16, 17]. This resulted in a relatively favorable
pathological N-status in our cohort, with pN0 in 78.5 %,
pN1mi in 4.5 %, pN1 in 12.3 %, and pN2–3 in 3.6 %. The
rate of lymph node positive disease in these TNBC patients
seems to correspond to other breast cancer subtypes.
Regardless of the receptor status, a cohort study of 12,113
patients with clinically T1-2N0 breast cancer, who were
treated with breast conserving therapy, revealed pN0 in
79.8 %, pN1mi in 7.3 %, pN1 in 11.1 %, and pN2-3 in
1.7 % [17].
Fig. 1 Axillary lymph node staging and treatment results of the 2548 triple-negative breast cancer patients. TNBC Triple-negative breast cancer,
SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, SLN sentinel lymph node, and cALND completion axillary lymph node
dissection
Table 2 Administered adjuvant chemotherapy per age category
Age category No chemotherapy Chemotherapy Total
20–30 year, n (%) 2 (3.3) 58 (96.7) 60 (2.4)
31–40 year, n (%) 23 (7.4) 286 (92.6) 309 (12.1)
41–50 year, n (%) 96 (17.2) 462 (82.8) 558 (21.9)
51–60 year, n (%) 191 (29.1) 465 (70.9) 656 (25.7)
61–70 year, n (%) 261 (50.5) 256 (49.5) 517 (20.3)
C70 year, n (%) 441 (98.4) 7 (1.6) 448 (17.6)
Total 1014 (39.8) 1534 (60.2) 2548
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Several studies investigated the association between
tumor subtype and nodal status, and showed that the inci-
dence of lymph node metastases in TNBC is equal or even
lower compared to ER-positive or HER2-positive tumors
[18–22]. TNBC is associated with similar characteristics
that are related to lymph node involvement, such as
younger age and higher tumor grade; though, there is no
association between TNBC and lymphovascular invasion
[2, 8, 19]. The study of Ugras et al. revealed that all breast
cancer subtypes were independently associated with lym-
phovascular invasion (p\ 0.0001), with TNBC having the
lowest incidence of lymphovascular invasion, which might
explain a lower incidence of node positivity in some
cohorts [18, 22].
Main focus of our study was the occurrence of regional
recurrences in TNBC. Only 25 patients (1.0 %) in our
cohort experienced a solitary regional recurrence and 50
patients (1.9 %) experienced regional recurrence together
with a local and/or distant event. In literature, one other
study reported specifically on regional recurrence in
TNBC. It concerned a prospective database review ques-
tioning the safety of breast conserving therapy in TNBC.
This study included 1851 patients with stage I to III breast
cancer who were treated with breast conserving therapy, of
whom 234 patients had TNBC. They revealed a regional
recurrence rate of 1.3 % at a median follow-up of 5 years
in the TNBC group and 4.7 % local recurrences, which
were comparable to the total patient group (1.1 % regional
recurrences and 2.5 % local recurrences) [9]. Distant
recurrence occurred in 9.0 % of patients with TNBC,
compared to 3.6 % for all patients together. A significant
difference for distant recurrence was found between TNBC
and patients with a luminal A subtype (positive for ER or
PR and negative for HER2) (p = 0.001).
No further studies have been published on regional
recurrence in TNBC, although there have been several
studies on local recurrence, more specifically comparing
breast conserving therapy and mastectomy. These studies
showed that there is a higher rate of local recurrence in
TNBC, compared to other subtypes, without significant
differences for type of local breast treatment [1, 9, 23, 24,
25]. However, in one study, the increased local recurrence
rate for TNBC lost significance after adjustments for fac-
tors such as age, tumor size, and grade [9]. Local recur-
rence rates of 4.2–10 % are reported, which is slightly
higher than in current study, presumably due to the fact that
we included only clinically T1-2N0 patients [1, 9, 24, 25].
Table 3 Characteristics of patients with a regional event diagnosed
during follow-up
Regional event
Number of events, % 75 (2.9)
Median time to event in years, range 1.6 (0.1–4.9)
Interquartile range time to event, years
25 % 0.8
75 % 2.5
Mean age at initial diagnosis, SD 54 (14.7)
Clinical T-status, n (%)
cT1 40 (53.3)
cT2 35 (46.7)
Local treatment breast, n (%)
BCT 37 (49.3)
Mastectomy 31 (41.3)
Mastectomy ? RT 2 (2.7)
Lumpectomy 5 (6.7)
Axillary surgery, n (%)
SLNB only 45 (60.0)
ALND 1 (1.3)
SLNB and cALND 29 (38.7)
No axillary surgery –
Chemotherapy, n (%)
Yes 45 (60.0)
No 30 (40.0)
Pathological T-stadium, n (%)
pT1 31 (41.3)
pT2 42 (56.0)
pT3 1 (1.3)
Unknown 1 (1.3)
Pathological N-stadium, n (%)
pN0 39 (52.0)
pN0(i?) 2 (2.7)
pN1mi 5 (6.7)
pN1 19 (25.3)
pN2 3 (4.0)
pN3 2 (2.7)
Unknown 5 (6.7)
Grade, n (%)
Grade 1 1 (1.3)
Grade 2 11 (14.7)
Grade 3 61 (81.3)
Unknown 1 (2.7)
Recurrences, n (%)
Regional 25 (33.3)
Regional and local 10 (13.3)
Regional and distant 28 (37.3)
Table 3 continued
Regional event
Regional, local and distant 12 (16.0)
N number of cases, SD standard deviation, BCT breast conserving
therapy, RT radiotherapy, SLNB sentinel lymph node biopsy, ALND
axillary lymph node dissection, Grade according to modified Bloom–
Richardson
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The median time to any recurrence in TNBC is short
compared to other subtypes, and almost all events occur
within 5 years after diagnosis [26, 27]. This is also the case
in our cohort, where the median time to any recurrence was
1.7 years, with even 75 % of all events within 3 years after
diagnosis.
The systemic treatment option for TNBC is, until now,
limited to chemotherapy. In neoadjuvant chemotherapy
trials, pathological complete response (PCR) rates of pri-
mary tumor and lymph nodes are reported in up to 40 % in
the TNBC subtype [28–32]. PCR provides prognostic
information for TNBC as well as for HER2-positive (ER/
PR negative) patients. A meta-analysis of Cortazar et al.
evaluated 11,955 patients from neoadjuvant chemotherapy
trials and showed a PCR in 34 % of TNBC patients [32].
Event-free survival and overall survival were improved in
patients achieving PCR, with a hazard ratio of 0.24 (95 %
CI 0.18–0.33) and 0.16 (95 % CI 0.11–0.25), respectively.
Adjuvant chemotherapy was administered to 60 % of
patients in our cohort. Patients treated with neoadjuvant
chemotherapy were not included. The indications for
adjuvant chemotherapy have been expanded over the years.
Comparison of the 2005 and current 2012 Dutch breast
cancer guideline shows some changes in indications [14,
33]. Chemotherapy is now indicated in case of a primary
tumor size [2 cm (vs. C3 cm), and 1–2 cm and tumor
grade 2–3 (vs. 1–2 cm and tumor grade 3). Considering
elderly, current Dutch guideline now considers
chemotherapy for fit patients aged 70 years or older who
are pathological lymph node positive. There further have
been some changes in the regimen of adjuvant
chemotherapy. Six cycles of TAC is still commonly
administered in current practice, but FEC is nowadays
combined with a taxane, and antracycline-based
chemotherapy can be administered in combination with a
taxane [33]. Preliminary research has shown that the
addition of carboplatin to a taxane increases the PCR rate
in TNBC, though no survival data are available yet [34].
Changements in indications and regimen of chemotherapy
are likely to positively influence patients outcome.
Conclusion
Triple-negative clinically T1-2N0 breast cancer patients
rarely develop a regional recurrence. Their disease-free
survival is more threatened by distant recurrence, which
affects their overall survival. Consequently, it seems jus-
tified to include triple-negative breast cancer patients in
randomized controlled trials investigating the safety of
minimizing axillary treatment.
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